Understanding BTK Inhibitors and Effective Therapies in PCNSL

Christian Grommes, MD, discusses how BTK inhibitors and CAR T-cell therapy fit into the relapsed/refractory primary CNS lymphoma treatment paradigm.

Christian Grommes, MD, and Ashley Sumrall, MD, FACP, FASCO, discuss the phase 3 IGNITE trial of tirabrutinib in PCNSL.

Ashley Sumrall, MD, FACP, FASCO, discusses emerging data for tirabrutinib and the evolving role of CAR T-cell therapy in primary central nervous system lymphoma.

Ashley Sumrall, MD, FACP, FASCO, discusses CAR T-cell therapies and BTK inhibitors in primary central nervous system lymphoma and the role they play.

Christopher R. D’Angelo, MD, discusses the BTK inhibitors and their role in primary central nervous system lymphoma.